Literature DB >> 8901846

Tamoxifen: the long and short of it.

S M Swain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8901846     DOI： 10.1093/jnci/88.21.1516

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio.

Authors:  Peter Blaha; Ruth Exner; Andrea Dal Borgo; Sinda Bigenzahn; Peter Panhofer; Otto Riedl; Sebastian Schoppmann; Thomas Bachleitner-Hofmann; Emanuel Sporn; Ursula Pluschnig; Florian Fitzal; Guenther Steger; Raimund Jakesz; Peter Dubsky; Michael Gnant
Journal:  Breast Care (Basel)       Date:  2009-06-23       Impact factor: 2.860

Review 2.  Breast cancer (non-metastatic).

Authors:  Justin Stebbing; Geoff Delaney; Alastair Thompson
Journal:  BMJ Clin Evid       Date:  2011-02-08

Review 3.  Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.

Authors:  Walter Jonat; Felix Hilpert
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-01       Impact factor: 4.553

4.  Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.

Authors:  Christoph Mundhenke; Christian Schem; Walter Jonat
Journal:  Breast Care (Basel)       Date:  2008-10-21       Impact factor: 2.860

5.  Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.

Authors:  Alexander A Parent; Jillian R Gunther; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

Review 6.  Breast cancer (non-metastatic).

Authors:  Justin Stebbing; Geoff Delaney; Alistair Thompson
Journal:  BMJ Clin Evid       Date:  2007-12-04

7.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

8.  The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.

Authors:  Takayoshi Kiba; Takashi Inamoto; Tsutomu Nishimura; Masaya Ueno; Kazuhiro Yanagihara; Satoshi Teramukai; Hironori Kato; Masakazu Toi; Masanori Fukushima
Journal:  BMC Cancer       Date:  2008-11-07       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.